ENTITY
Biogen

Biogen (BIIB UW)

1
Analysis
Health CareUnited States
Biogen Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company products address diseases such as multiple sclerosis, non-hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
more
29 Oct 2018 13:52

Smartkarma’s Week That Was in JP/​​​​KR: Market Turbulence 10 Years After 2008, Coway, & Celltrion

The Korean and Japanese stock markets have fallen sharply in October. Nikkei is down 12% and KOSPI is down 14% in October. It has been 10 years...

Logo
413 Views
Share
22 Oct 2018 22:52

Samsung BioLogics Update

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...

Share
bullishEisai Co Ltd
03 Jul 2018 20:11

Merck Alliance Provides Stability to Deal With the Outcome of High Risk Alzheimer’s R&D in FY19

We upgrade Eisai Co Ltd (4523 JP) to “Equal-weight” after reviewing our model post FY17 (YE Mar-18) earnings, in light of the augmented peak sales...

30 Jun 2018 07:59

Biogen Exercises Samsung Bioepis Call Option - Summary & Implications

Samsung Biologics Co., Ltd (207940 KS) said in a regulatory filing that Biogen Inc (BIIB US) exercised Bioepis call option. Link of this...

Logo
336 Views
Share
x